Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease

Exclusion Criteria

• •1. Subject is receiving therapy with anti-Parkinson's disease drugs(include levodopa (L-DOPA), amantadine, anticholinergics, monoamine oxidase (MAO) B inhibitors, dopamine receptor agonists or catechol-O-methyltransferase inhibitor),which is not under the guidance of professional doctors,either concurrently or within 28 days prior to the Baseline Visit.
• •2. Subject is receiving therapy with 1 of the following drugs, either concurrently or within 28 days prior to the Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine, sibelium ,neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, and quetiapine), monoamine oxidase-A (MAO-A) inhibitors, methylphenidate, amphetamine.
• •3. Subject is receiving central nervous system (CNS) therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors \[SSRIs\], anxiolytics, or other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to the Baseline Visit and is likely to remain stable for the duration of the study
• •4. Subject has visual hallucination,and the visual hallucination happened within 1 year after been diagnosed with PD.
• •5. Subject has delirium。
• •6. Subject has Other digestive, Urological , blood system , endocrine , immune system or cardiopulmonary problems that in the view of the researchers.
• •7. Subject has Serum creatinine≥97umol/L；or the alanine aminotransferase(ALT) ≥40U/L;or aspartate aminotransferase≥40U/L。
• •8. Subject has a epilepsy history.
• •9. Subject has evidence of an impulse control disorder, a history of mental illness, thoughts or behaviors of suicide.
• •10. According to the assessment of the investigator,Subject cann't complete the study due to poor compliance, drug or Alcohol abuse.
• •11. Subject is participating in other clinical trials or Participated in the past 2 weeks.